News
European and FDA approval of Sephience (sepiapterin) with broad labeling for PKU - - Global launch underway in Europe and U.S. - - Total Q2 Revenue of $179M - ...
LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable ...
Consumer Reports and Unleaded Kids evaluated baby food brands for compliance with California’s AB899 requiring heavy metal ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif., August 06, ...
Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...
Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...
August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.681 EPS, expectations ...
Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand ...
Zacks Investment Research on MSN3d
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Which One is Right for You?Botulinum toxin injections are among the most popular non-surgical cosmetic treatments available today, offering effective solutions for reducing wrinkles and fine lines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback